- Confirmed by DR. Reddy laboratories, Hyderabad
- Clinical Trials for phase 2, 3 to be done
- Sputnik V has been found 92% effective in fighting Corona virus
Hyderabad: Sputnik V vaccine has arrived in India for the clinical trials of phase 2, and 3 to be conducted by Dr. Reddy laboratories in coming days. Along with trails, there will be a study on immunogenicity and safety of the drug.
This step was taken after green signal from DCGI was given to Reddy’s to go ahead with the trails. Dr. Reddy’s will conduct these trails along with collaboration of Biotechnology Industry Research Assistance Council (BIRAC) which was set up by Central govt.
Sputnik V is the first vaccine to be registered against COVID 19 in the world in the month of August 2020. Russian Direct Investment fund (RDIF) will release 100 million of doses after Regulatory approval to Dr. Reddy’s.
Recently Pfizer came up with a statement that their vaccine is 90% effective in preventing Covid-19 after completions of 3 phases of human clinical trials. Now it is a ray of hope for the world that Pfizer’s vaccine, Sputnik V and Bharath Biotech ’Covaxin’, which is in phase 3 clinical trials, can prevent COVID 19 virus.
Also Read: COVID: India Prepares Blueprint For Vaccine Supply